Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury
Ram Kuwar, Andrew Rolfe, Long Di, et al.
Journal of Neuroinflammation (2019) Vol. 16, Iss. 1
Open Access | Times Cited: 161

Showing 1-25 of 161 citing articles:

Pharmacological Inhibitors of the NLRP3 Inflammasome
Ayesha Zahid, Bofeng Li, Arnaud John Kombe Kombe, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 551
NLRP3 Inflammasome and Inflammatory Diseases
Zheng Wang, Simei Zhang, Ying Xiao, et al.
Oxidative Medicine and Cellular Longevity (2020) Vol. 2020, pp. 1-11
Open Access | Times Cited: 270
The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases
Hallie Blevins, Yiming Xu, Savannah Biby, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 255
Microglial Depletion with CSF1R Inhibitor During Chronic Phase of Experimental Traumatic Brain Injury Reduces Neurodegeneration and Neurological Deficits
Rebecca J. Henry, Rodney M. Ritzel, James P. Barrett, et al.
Journal of Neuroscience (2020) Vol. 40, Iss. 14, pp. 2960-2974
Open Access | Times Cited: 243
The NLRP3 inflammasome in traumatic brain injury: potential as a biomarker and therapeutic target
William T. O’Brien, Louise Pham, Georgia F. Symons, et al.
Journal of Neuroinflammation (2020) Vol. 17, Iss. 1
Open Access | Times Cited: 174
Targeting microglial autophagic degradation in NLRP3 inflammasome-mediated neurodegenerative diseases
Anguo Wu, Xiaogang Zhou, Gan Qiao, et al.
Ageing Research Reviews (2020) Vol. 65, pp. 101202-101202
Closed Access | Times Cited: 155
Microglia and Neuroinflammation: Crucial Pathological Mechanisms in Traumatic Brain Injury-Induced Neurodegeneration
Fangjie Shao, Xiaoyu Wang, Haijian Wu, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 135
The Role of NLRP3 Inflammasome in Alzheimer’s Disease and Potential Therapeutic Targets
Tao Liang, Yang Zhang, Suyuan Wu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 125
New insight into neurological degeneration: Inflammatory cytokines and blood–brain barrier
Jie Yang, Mingzi Ran, Hongyu Li, et al.
Frontiers in Molecular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 112
Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction
Qiang Ma
Pharmacological Reviews (2023) Vol. 75, Iss. 3, pp. 487-520
Open Access | Times Cited: 78
Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review)
Xiaolu Zhang, Ziyu Wang, Yujia Zheng, et al.
International Journal of Molecular Medicine (2023) Vol. 51, Iss. 4
Open Access | Times Cited: 57
Inflammasomes in neurological disorders — mechanisms and therapeutic potential
Kishore Aravind Ravichandran, Michael T. Heneka
Nature Reviews Neurology (2024) Vol. 20, Iss. 2, pp. 67-83
Closed Access | Times Cited: 34
Targeting pyroptosis with nanoparticles to alleviate neuroinflammatory for preventing secondary damage following traumatic brain injury
Xuefeng Zhang, Xuyang Huang, Diancheng Hang, et al.
Science Advances (2024) Vol. 10, Iss. 2
Open Access | Times Cited: 23
Combination therapies and other therapeutic approaches targeting the NLRP3 inflammasome and neuroinflammatory pathways: a promising approach for traumatic brain injury
Zana Montazeri-Khosh, Ahmad Ebrahimpour, Mina Keshavarz, et al.
Immunopharmacology and Immunotoxicology (2025), pp. 1-17
Closed Access | Times Cited: 2
Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR‐141‐mediated NLRP3 inflammasome and TGF‐β1/Smads signaling in diabetic cardiomyopathy
Hui Che, Yueqiu Wang, Hui Li, et al.
The FASEB Journal (2020) Vol. 34, Iss. 4, pp. 5282-5298
Closed Access | Times Cited: 132
The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer’s Disease
Courtney M. Kloske, Donna M. Wilcock
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 129
Inhibiting the NLRP3 Inflammasome
Lina Y. El‐Sharkawy, David Brough, Sally Freeman
Molecules (2020) Vol. 25, Iss. 23, pp. 5533-5533
Open Access | Times Cited: 93
Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases
Jin Kyung Seok, Han Chang Kang, Yong‐Yeon Cho, et al.
Archives of Pharmacal Research (2021) Vol. 44, Iss. 1, pp. 16-35
Open Access | Times Cited: 88
The Role of NLRP3 Inflammasome in the Pathogenesis of Traumatic Brain Injury
Natasha Irrera, Massimo Russo, Giovanni Pallio, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 17, pp. 6204-6204
Open Access | Times Cited: 85
Dihydrolipoic acid protects against lipopolysaccharide-induced behavioral deficits and neuroinflammation via regulation of Nrf2/HO-1/NLRP3 signaling in rat
Hetao Bian, Gaohua Wang, Junjie Huang, et al.
Journal of Neuroinflammation (2020) Vol. 17, Iss. 1
Open Access | Times Cited: 84
Pathway network of pyroptosis and its potential inhibitors in acute kidney injury
Ning Li, Yuru Wang, Xinyue Wang, et al.
Pharmacological Research (2021) Vol. 175, pp. 106033-106033
Closed Access | Times Cited: 75
Atorvastatin ameliorates early brain injury after subarachnoid hemorrhage via inhibition of pyroptosis and neuroinflammation
Junhui Chen, Chun-Lei Zhang, Tengfeng Yan, et al.
Journal of Cellular Physiology (2021) Vol. 236, Iss. 10, pp. 6920-6931
Closed Access | Times Cited: 65
The Role of NLRP3 Inflammasome in Cerebrovascular Diseases Pathology and Possible Therapeutic Targets
Rongrong Bai, Yue Lang, Jie Shao, et al.
ASN NEURO (2021) Vol. 13, pp. 175909142110181-175909142110181
Open Access | Times Cited: 61
Nose-to-brain delivery of chrysin transfersomal and composite vesicles in doxorubicin-induced cognitive impairment in rats: Insights on formulation, oxidative stress and TLR4/NF-kB/NLRP3 pathways
Shaimaa S. Ibrahim, Omar G. Abo Elseoud, Mohamed H. Mohamedy, et al.
Neuropharmacology (2021) Vol. 197, pp. 108738-108738
Closed Access | Times Cited: 58
Intranasally administered human MSC-derived extracellular vesicles inhibit NLRP3-p38/MAPK signaling after TBI and prevent chronic brain dysfunction
Maheedhar Kodali, Leelavathi N. Madhu, Roxanne L. Reger, et al.
Brain Behavior and Immunity (2022) Vol. 108, pp. 118-134
Open Access | Times Cited: 49
Page 1 - Next Page

Scroll to top